Literature DB >> 24810138

An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index.

Meenakshi Bewtra1, Colleen M Brensinger, Vesselin T Tomov, Tram B Hoang, Carly E Sokach, Corey A Siegel, James D Lewis.   

Abstract

BACKGROUND: There is a need for simple, noninvasive patient-driven disease assessment instruments in ulcerative colitis (UC). We sought to further assess and refine the previous described 6-point Mayo score.
METHODS: A cross-sectional study of 282 UC patients was conducted assessing the correlation of the 2 patient-reported Mayo score components (6-point Mayo score) with the simple clinical colitis activity index (SCCAI) and a single Likert scale of patient-reported disease activity. Spearman's correlation, sensitivity, specificity, and area under the receiver operating curves (AUC) were calculated. A separate validation study in 59 UC patients was also conducted.
RESULTS: Participants predominantly had long-standing disease (83%) and were in self-reported remission (63%). The 6-point Mayo score correlated well with the SCCAI (rho = 0.71; P < 0.0001) and patient-reported disease activity (rho = 0.65; P < 0.0001). Using a cutpoint of 1.5, the 6-point Mayo score had 83% sensitivity and 72% specificity for patient-defined remission, and 89% sensitivity and 67% specificity for SCCAI-defined remission (score, <2.5). The 6-point Mayo score and SCCAI had similar accuracy of predicting patient-defined remission (AUC = 0.84 and 0.87, respectively). Addition of the SCCAI general well-being question to the 6-point Mayo improved the predictive ability for patient-defined remission; and a new weighted score had an AUC of 0.89 in the development cohort and 0.93 in the validation cohort. The optimal cutpoint was 1.6.
CONCLUSIONS: The patient-reported UC severity index that includes stool frequency, bleeding, and general well-being accurately measures clinical disease activity without requiring direct physician contact.

Entities:  

Mesh:

Year:  2014        PMID: 24810138      PMCID: PMC4137887          DOI: 10.1097/MIB.0000000000000053

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  13 in total

Review 1.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.

Authors:  Geert D'Haens; William J Sandborn; Brian G Feagan; Karel Geboes; Stephen B Hanauer; E Jan Irvine; Marc Lémann; Philippe Marteau; Paul Rutgeerts; Jurgen Schölmerich; Lloyd R Sutherland
Journal:  Gastroenterology       Date:  2006-12-20       Impact factor: 22.682

2.  Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis.

Authors:  P D R Higgins; M Schwartz; J Mapili; I Krokos; J Leung; E M Zimmermann
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

3.  Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?

Authors:  Peter D R Higgins; Marc Schwartz; John Mapili; Ellen M Zimmermann
Journal:  Am J Gastroenterol       Date:  2005-02       Impact factor: 10.864

4.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

Authors:  K W Schroeder; W J Tremaine; D M Ilstrup
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

5.  Health-related quality of life correlates with clinical and endoscopic activity indexes but not with demographic features in patients with ulcerative colitis.

Authors:  Alexandra Zahn; Ulf Hinz; Max Karner; Robert Ehehalt; Wolfgang Stremmel
Journal:  Inflamm Bowel Dis       Date:  2006-11       Impact factor: 5.325

6.  Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis.

Authors:  James D Lewis; Shaokun Chuai; Lisa Nessel; Gary R Lichtenstein; Faten N Aberra; Jonas H Ellenberg
Journal:  Inflamm Bowel Dis       Date:  2008-12       Impact factor: 5.325

7.  A simple clinical colitis activity index.

Authors:  R S Walmsley; R C Ayres; R E Pounder; R N Allan
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

8.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

9.  Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort.

Authors:  Kathrine Frey Frøslie; Jørgen Jahnsen; Bjørn A Moum; Morten H Vatn
Journal:  Gastroenterology       Date:  2007-06-02       Impact factor: 22.682

10.  Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk.

Authors:  M D Rutter; B P Saunders; K H Wilkinson; S Rumbles; G Schofield; M A Kamm; C B Williams; A B Price; I C Talbot; A Forbes
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

View more
  13 in total

1.  Measurement of Inflammatory Bowel Disease Symptoms: Reliability of an Abbreviated Approach to Data Collection.

Authors:  Maria Paula Henao; Meenakshi Bewtra; Mark T Osterman; Faten N Aberra; Frank I Scott; Gary R Lichtenstein; Jennifer Kraschnewski; James D Lewis
Journal:  Inflamm Bowel Dis       Date:  2015-10       Impact factor: 5.325

2.  Transcriptional factor ATF3 protects against colitis by regulating follicular helper T cells in Peyer's patches.

Authors:  Yingjiao Cao; Qiong Yang; Hui Deng; Jinyi Tang; Jiancong Hu; Huanliang Liu; Min Zhi; Linsen Ye; Bin Zou; Yongdong Liu; Lai Wei; Dmitry I Gabrilovich; Haikun Wang; Jie Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-12       Impact factor: 11.205

3.  Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis.

Authors:  Burcin Özdirik; Martin Maibier; Maria Scherf; Jule Marie Nicklaus; Josephine Frohme; Tobias Puengel; Dirk Meyer Zum Büschenfelde; Frank Tacke; Tobias Mueller; Michael Sigal
Journal:  J Clin Med       Date:  2022-04-28       Impact factor: 4.964

4.  Urgency and Its Association With Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis.

Authors:  Jared A Sninsky; Edward L Barnes; Xian Zhang; Millie D Long
Journal:  Am J Gastroenterol       Date:  2022-02-15       Impact factor: 12.045

5.  Diffusion-weighted magnetic resonance imaging without bowel preparation for detection of ulcerative colitis.

Authors:  Li-Li Yu; Hai-Shan Yang; Bu-Tian Zhang; Zhong-Wen Lv; Fu-Rong Wang; Chun-Yu Zhang; Wei-Bo Chen; Hui-Mao Zhang
Journal:  World J Gastroenterol       Date:  2015-09-07       Impact factor: 5.742

6.  Questionnaire assessment helps the self-management of patients with inflammatory bowel disease during the outbreak of Coronavirus Disease 2019.

Authors:  Meiping Yu; Zhenghao Ye; Yu Chen; Tingting Qin; Jiguang Kou; De'an Tian; Fang Xiao
Journal:  Aging (Albany NY)       Date:  2020-07-03       Impact factor: 5.682

7.  Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach.

Authors:  Silvio Danese; Rupa Banerjee; Jr Fraser Cummings; Iris Dotan; Paulo G Kotze; Rupert Wing Loong Leong; Kristine Paridaens; Laurent Peyrin-Biroulet; Glyn Scott; Gert Van Assche; Jan Wehkamp; Jesús K Yamamoto-Furusho
Journal:  Intest Res       Date:  2018-10-16

8.  Prevalence and risk factors of bowel symptoms in Korean patients with ulcerative colitis in endoscopic remission: a retrospective study.

Authors:  Kwangwoo Nam; Sang Hyoung Park; Jun Ho Oh; Ho-Su Lee; Soomin Noh; Jae Cheol Park; Jin Yong Kim; Eun Hye Oh; Jeongseok Kim; Nam Seok Ham; Sung Wook Hwang; Dong-Hoon Yang; Byong Duk Ye; Jeong-Sik Byeon; Seung-Jae Myung; Suk-Kyun Yang
Journal:  BMC Gastroenterol       Date:  2021-01-06       Impact factor: 3.067

9.  Using item response theory (IRT) to improve the efficiency of the Simple Clinical Colitis Activity Index (SCCAI) for patients with ulcerative colitis.

Authors:  Alissa Walsh; Rena Cao; Darren Wong; Ramona Kantschuster; Lawrence Matini; Jean Wilson; Andrey Kormilitzin; Matthew South; Simon Travis; Sarah Bauermeister
Journal:  BMC Gastroenterol       Date:  2021-03-22       Impact factor: 3.067

10.  Systematic Review of Development and Content Validity of Patient-reported Outcome Measures in Inflammatory Bowel Disease: Do We Measure What We Measure?

Authors:  Emma M van Andel; Brechtje D M Koopmann; Femke Crouwel; Casper G Noomen; Nanne K H de Boer; Dirk P van Asseldonk; Lidwine B Mokkink
Journal:  J Crohns Colitis       Date:  2020-09-16       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.